Echo IQ has developed an AI diagnostic tool that will revolutionise the diagnosis of structural heart disease. Specifically, it is designed to reduce the incidence of undetected and misdiagnosed cardiac issues.
Prof Geoffrey A. Strange, PhD; Prof Michael P. Feneley, MD; Prof David Prior, MBBS PhD; Prof David Muller, MD; Dr Prasanna Venkataraman, MD; Dr Yiling Situ, MBBS; Prof Simon Stewart, DMSc; Prof David Playford, MBBS PhD
Professor Geoff Strange
The University of Notre Dame Australia
32 Mouat St, Fremantle WA 6160
E: [email protected]
T: +61 422 308 585
When compared to routine clinical detection and management, can machine learning/artificial intelligence (AI) techniques augment the detection of guideline-defined severe AS with potential to redirect more women and men to appropriate management?
An AI automated alert system (AI-AAS) specifically designed to detect severe AS
from routinely reported echocardiographic measurements, has the potential to
redirect 1.6 to 2.1-fold more men and women with guideline-defined severe AS
towards more definitive care from the heart care team.
A significant proportion of individuals (particularly women) being managed within a high-quality tertiary referral setting are potentially being overlooked for management of guideline defined, severe AS. If routinely applied, an AI-AAS has strong potential to appropriately redirect these individuals towards (consideration of) this life-saving treatment.
Echo IQ has developed an AI diagnostic tool that will revolutionise the diagnosis of structural heart disease. Specifically, it is designed to reduce the incidence of undetected and misdiagnosed cardiac issues.
EchoSolv™ is currently available in the US and Australia as a guideline-led decision-support tool. Full
phenotyping capabilities will be available pending FDA approval.
All rights reserved. Copyright © 2023 Echo IQ.
Designed and Developed by Brand for Brands.